ExpiresAugust 18, 2022
CME Provider: Potomac Center for Medical Education
Description of CME Course
The incidence of nonmelanoma skin cancers (NMSC), including cutaneous squamous cell carcinomas (CSCC) and basal cell carcinomas (BCC), is increasing globally. Although these cancers are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, are not amenable to those standard options, and historically, have had few treatment options. Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.
The CME program, Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas, will provide oncologists with current guideline-based diagnostic, staging, and treatment strategies for patients with advanced BCC and CSCC as well as how newly approved and agents in development fit into treatment strategies.
ABMS Member Board Approvals by Type
ABMS MOC Part II CME Activity
NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
-Make timely diagnoses of patients with BCC or CSCC using current evidence-based criteria
-Accurately stage and risk stratify patients with BCC or CSCC to establish optimal follow-up regimens
-Make evidence-based treatment selections for patients with advanced BCC or CSCC
-Assess the safety and efficacy of emerging therapies for advanced BCC or CSCC
Basal cell carcinoma, Cutaneous squamous cell carcinoma, Checkpoint inhibitor, PD-1 treatment, nonmelanoma skin cancer
Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement
CME Credit Type
AMA PRA Category 1 Credit
Academic Medicine, Inpatient, Outpatient, VA/Military